Overview

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Status:
Withdrawn
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of BMS-986094 and Daclatasvir (DCV) when given in combination with or without Ribavirin
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Ribavirin